BACKGROUND: Although nocturnal awakenings help categorize asthma severity and control, their clinical significance has not been thoroughly studied. OBJECTIVE: We sought to determine the clinical consequences of nocturnal asthma symptoms requiring albuterol (NASRAs) in children with mild-to-moderate persistent asthma outside of periods when oralcorticosteroids were used for worsening asthma symptoms. METHODS:Two hundred eighty-five children aged 6 to 14 years with mild-to-moderate persistent asthma were randomized to receive one of 3 controller regimens and completed daily symptom diaries for 48 weeks. Diary responses were analyzed for the frequency and consequences of NASRAs. RESULTS:NASRAs occurred in 72.2% of participants at least once, and in 24.3% of participants, they occurred 13 or more times. The majority (81.3%) of nocturnal symptoms occurred outside of exacerbation periods and were associated the next day with the following events: albuterol use (56.9% of days preceded by nocturnal symptoms vs 18.1% of days not preceded by nocturnal symptoms; relative risk [RR], 2.3; 95% CI, 2.2-2.4), school absence (5.0% vs 0.3%; RR, 10.6; 95% CI, 7.8-14.4), and doctor contact (3.7% vs 0.2%; RR, 8.8; 95% CI, 6.1-12.5). Similar findings were noted during exacerbation periods (RRs of 1.7 for albuterol use, 5.5 for school absence, and 4.9 for doctor contacts). Nocturnal symptoms did not predict the onset of exacerbations. CONCLUSION:Nocturnal symptoms requiring albuterol in children with mild-to-moderate persistent asthma receiving controller therapy occurred predominantly outside of exacerbation periods. Despite being poor predictors of exacerbations, they were associated with increases in albuterol use, school absences, and doctor contacts the day after nocturnal symptom occurrences.
RCT Entities:
BACKGROUND: Although nocturnal awakenings help categorize asthma severity and control, their clinical significance has not been thoroughly studied. OBJECTIVE: We sought to determine the clinical consequences of nocturnal asthma symptoms requiring albuterol (NASRAs) in children with mild-to-moderate persistent asthma outside of periods when oral corticosteroids were used for worsening asthma symptoms. METHODS: Two hundred eighty-five children aged 6 to 14 years with mild-to-moderate persistent asthma were randomized to receive one of 3 controller regimens and completed daily symptom diaries for 48 weeks. Diary responses were analyzed for the frequency and consequences of NASRAs. RESULTS: NASRAs occurred in 72.2% of participants at least once, and in 24.3% of participants, they occurred 13 or more times. The majority (81.3%) of nocturnal symptoms occurred outside of exacerbation periods and were associated the next day with the following events: albuterol use (56.9% of days preceded by nocturnal symptoms vs 18.1% of days not preceded by nocturnal symptoms; relative risk [RR], 2.3; 95% CI, 2.2-2.4), school absence (5.0% vs 0.3%; RR, 10.6; 95% CI, 7.8-14.4), and doctor contact (3.7% vs 0.2%; RR, 8.8; 95% CI, 6.1-12.5). Similar findings were noted during exacerbation periods (RRs of 1.7 for albuterol use, 5.5 for school absence, and 4.9 for doctor contacts). Nocturnal symptoms did not predict the onset of exacerbations. CONCLUSION: Nocturnal symptoms requiring albuterol in children with mild-to-moderate persistent asthma receiving controller therapy occurred predominantly outside of exacerbation periods. Despite being poor predictors of exacerbations, they were associated with increases in albuterol use, school absences, and doctor contacts the day after nocturnal symptom occurrences.
Authors: Robert C Strunk; Alice L Sternberg; Leonard B Bacharier; Stanley J Szefler Journal: J Allergy Clin Immunol Date: 2002-09 Impact factor: 10.793
Authors: Daphne Koinis-Mitchell; Sheryl J Kopel; Ronald Seifer; Monique LeBourgeois; Elizabeth L McQuaid; Cynthia A Esteban; Julie Boergers; Jack Nassau; Michael Farrow; Gregory K Fritz; Robert B Klein Journal: Sleep Health Date: 2017-04-11
Authors: Daphne Koinis-Mitchell; Sheryl J Kopel; Michael L Farrow; Elizabeth L McQuaid; Jack H Nassau Journal: Ann Allergy Asthma Immunol Date: 2019-03-11 Impact factor: 6.347
Authors: Cynthia A Esteban; Robin S Everhart; Sheryl J Kopel; Robert B Klein; Daphne Koinis-Mitchell Journal: Ann Allergy Asthma Immunol Date: 2017-09 Impact factor: 6.347
Authors: Kate E Powers; Elissa Jelalian; Shira Dunsiger; Michael Farrow; Luis G Miranda; Patricia Mitchell; Sheryl Kopel; Daphne Koinis-Mitchell Journal: Pediatr Pulmonol Date: 2021-04-12
Authors: Giovanna Cilluffo; Giuliana Ferrante; Nicola Murgia; Rosanna Mancini; Simona Pichini; Giuseppe Cuffari; Vittoria Giudice; Nicolò Tirone; Velia Malizia; Laura Montalbano; Salvatore Fasola; Roberta Pacifici; Giovanni Viegi; Stefania La Grutta Journal: Int J Environ Res Public Health Date: 2022-02-05 Impact factor: 3.390